Monte Rosa Therapeutics Inc

NASDAQ:GLUE  
8.18
+0.34 (+4.34%)
Products

Monte Rosa Therapeutics announces FDA clearance of investigational new drug application for MRT-2359, GSPT1-directed molecular glue degrader

Published: 09/06/2022 11:52 GMT
Monte Rosa Therapeutics Inc (GLUE) - Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for Mrt-2359, a Gspt1-directed Molecular Glue Degrader.
Monte Rosa Therapeutics - on Track With Initiating a Phase 1/2 Clinical Trial of Mrt-2359 in Patients With Myc-driven Solid Tumors, Including Lung Cancer.
Monte Rosa Therapeutics Inc - Expects to Dose First Patient in Q4 of 2022.